Breast pain under the age of 50: is mammography really necessary?  by Foulkes, R.E. et al.
Abstracts / International Journal of Surgery 10 (2012) S1–S52S10
ABSTRACTStrust therefore only an additional cost of £10,000 per year would be
required for a dedicated anaesthetist.
0383: ARE THE NUMBER OF LYMPH NODES EXCISED DURING AXILLARY
NODE CLEARANCE SURGERY AFFECTED BY NEOADJUVANT
CHEMOTHERAPY?
David Naumann, Martin Sintler. Sandwell and West Birmingham Hospitals
NHS Trust, West Midlands, UK
Introduction: Neoadjuvant chemotherapy may change the macroscopic
architecture of lymph nodes (LNs) to such a degree that the number
counted by a histologist following axillary node clearance (ANC) is lower
than expected by the surgeon. We test the hypothesis that chemotherapy
prior to ANC reduces the number of LNs.
Methods: Retrospective study examining records for all patients under-
going ANC at a NHS Trust over a 17 month period. We compared the
number of LNs counted on histological examination between the patient
groups who had received neoadjuvant chemotherapy and those who had
not, with further subdivision into groups who had undergone sentinel
node biopsy (SNB) prior to ANC and those who had not.
Results: There were 237 ANC operations including 98 ANC alone, 36 ANC
following chemotherapy but no SNB, 61 ANC following SNB but no
chemotherapy, and 42 following both SNB and chemotherapy, yielding
14.4 (6.5), 13.0 (5.8), 14.3 (5.1), and 15.1 (5.5) mean LNs respectively
(p ¼ 0.398).
Conclusion:We ﬁnd no statistically signiﬁcant difference in the number of
LNs from excised axillary tissues between patients who received neo-
adjuvant chemotherapy and those who had not. Lower than expected
number of LNs may not credibly be attributed to neoadjuvant chemo-
therapy.
0387: BLUE DYE DIRECTED AXILLARY NODE SAMPLING- REVISITING
THE ROLE
Rachel French, Vijay Kurup. University Hospital North Tees, Stockton-on-
Tees, UK
Aim: To evaluate whether combination of Sentinel Lymph Node Bio-
psy(SLNB) using patent blue dye and four node sampling as a reasonable
alternative to SLNB (dual technique), in early breast cancer as guidelines
recommend.
Methods: A retrospective study of SLNB using patent blue dye and four
nodes sampling performed by a single surgeon from 2006-'11. All
245patients treated byWLE were included. SLN were localised by injecting
2 ml patent blue dye in the subareolar with further Level 1 sampling done
to achieve a minimum of 4 nodes, by palpation. Node positive axillae were
treated by radiotherapy or clearance as per MDT decision.
Results: The detection rate was 97.95% (240/245 patients). 41 patients had
axillary metastases- 38 cases SLN positive and 3 Negative. False negative
rate 1.5%, Sensitivity 92.7% and negative predictive value 98.5%. 21/
41patients (51.2%) had only one node involved in their axilla. Axillary
morbidity was minimal and recurrence nil at 5 years.
Conclusion: Injection technique and experience of surgeon can lead up to
98% SLN detection using blue dye alone with comparable false negativity.
Combining with four node sampling reduces the impact of false negativity
and avoids unnecessary axillary clearance in single node disease (51.2%).
0432: TRIPLE NEGATIVE BREAST CANCER; BACKGROUND, TREATMENT
AND FUTURE OPTIONS
Rebecca Watts-Cherry 1, Eleri Davies 2. 1Cardiff University, Cardiff, UK;
2 Llandough Hospital, Cardiff, UK
Aims: Identify a subgroup of patients who were diagnosed with triple
negative breast cancer (TNBC) in Cardiff and Vale (CAV) in 2006-2011, to
enable an understanding of how TNBC patients present, what treatment is
given and which patients had recurrences.
Method: This was a retrospective study. The pathology database gave a list
of TNBC patients. Using this information, the Clinical Portal and CANNISC
databases allowed the proforma to be completed, which was then ana-
lysed. All people diagnosed as having TNBC in CAV in 2006 - 2011 were
included. No age or gender restriction was imposed.
Results: 101 patients were included in the study, of these 77 (76%) are alive
up to 5 years after. 11 (11%) developed recurrences and 7 (7%) developedmetastasis. Of these 86% had grade 3 tumours (study average(sa)¼79%),
86% had invasive ductal carcinoma (sa¼ 87%) and the average size was
54mm (sa¼ 33mm). 67 (66%) patients received chemotherapy which was
found to enhance survival (p¼0.003).
Conclusion: TNBC disease is very responsive to chemotherapy agents, so
must be given to all triple-negative patients as routine treatment irre-
spective to the histological result. The results obtained compare appro-
priately with the majority of studies already conducted.
0438: DIFFERENCES IN PATIENT EXPERIENCE AND UNDERSTANDING OF
CONSENT WHEN CARRIED OUT IN CLINIC AND ON THE DAY OF
SURGERY
Amy Lord, Shehryer Naqvi, Ramesh Babu, Richard Sainsbury. St Mary's
Hospital, Isle of Wight, UK
Aims: To assess patients’ subjective perception of consent and recall of
information when comparing those consented in clinic with those con-
sented immediately before surgery.
Methods: Prospective study of patients undergoing breast and general
surgical operations. Patients were randomised to consent in clinic or
consent immediately before surgery. Patients completed a post-operative
questionnaire assessing satisfaction and recall of complications using
a tick-box list of 16 common complications, 6 of which were correct for
each operation. An overall score of correct minus incorrect answers was
calculated out of 6.
Results: 27 patients were included, 17 consented immediately pre-oper-
atively, and 10 in clinic (mean - 13 days pre-op). The mean overall score for
recollection of complications was 3 when consented on the day and 2.9
when consented in clinic. Subjective ratings of experience were not
signiﬁcantly different between the groups. Overall recall rates were better
for general complications (96% bleeding, 100% infection and 74% anaes-
thetic risk) than speciﬁc risks (25% seroma in breast patients).
Conclusions: In our experience patients can be consented either in clinic
or on the day of operation as there is no difference in their subjective
perceptions or recall of information. However only small numbers have
been assessed so far.
0457: IS MAMMOGRAM AN ESSENTIAL INVESTIGATION FOR DETECTING
BREAST CANCER IN PATIENTS YOUNGER THAN 40 YEARS?
Annabelle Williams, Rachel Hung, Yazan Masannat, Anil Desai, Prakash
Sinha. Princess Royal University Hospital, London, UK
Aims: Breast cancer is the commonest female cancer diagnosed in the UK.
In November 2010, the ‘Best Practice Diagnostic Guidelines for Patients
Presenting with Breast Symptoms' were amended. This study aims to
evaluate the safety of the proposed changes that statemammography is no
longer an essential ﬁrst line investigation for women under the age of 40,
with breast symptoms,
Methods: A retrospective cohort study of 40 patients, from January 2007
to July 2011, with histologically conﬁrmed breast cancer diagnosed when
under the age of 40 was performed by comparing mammography and
ultrasound results.
Results: All patients presented with a symptomatic lump and underwent
ultrasound scanning, mammography and core biopsy. No patient with
a normal ultrasound was found to have an abnormal mammogram. In all
40 patients ultrasound scanning showed 100% sensitivity in identifying the
breast lesions with 95% identiﬁed as indeterminate, suspicious or malig-
nant radiologically.
Conclusions: The new symptomatic breast guidelines are safe to imple-
ment, as ultrasound is an adequate ﬁrst line investigation. If any suspicious
ultrasound abnormality is detected then mammogram is essential for
further assessment as this could demonstrate further pathological changes
which may affect clinical management. This should lead to improved
patient care and resource management.
0471: BREAST PAIN UNDER THE AGE OF 50: IS MAMMOGRAPHY REALLY
NECESSARY?
R.E. Foulkes, R. Thomas, S. Ghosh. Nevill Hall Hospital, Abergavenny, UK
Aim: The aim of this study was to assess whether routine mammography
in patients presenting with painful breasts, and no palpable mass is
necessary in those under the age of 50 years.
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ABSTRACTSMethods: All patients attending breast clinic between 1st January 2008 -
31st December 2010 with breast pain only, undergoing mammography,
were assessed. Patients were then divided into the under 50 and over 50
age group for comparison.
Results: 315 patients were assessed, 168 (53%) were under 50 years old
(mean 43). All had clinically normal breasts on examination. Six (3.5%)
patients had indeterminate mammographic abnormalities in the under
50’s age group, versus eight (5%) in the over 50’s group. All had benign
ﬁndings following further investigation. One (0.6%) patient in the under
50’s group had a malignant mammographic abnormality - this was on the
asymptomatic side in a 48 year old. In those patients over 50 years, three
(2%) had malignant abnormalities on mammography, of which two were
conﬁrmed malignancies.
Conclusions:Malignancy is rare in patients under the age of 50 presenting
with pain only. In the setting of a normal clinical examination, routine
mammography is not necessary, and may lead to further unnecessary
investigations and anxiety.
0571: MAJOR BREAST AND AXILLARY SURGERY – FEASIBILITY OF A 23
HOUR PATHWAY
Rachel Clancy, Roger Watkins. Frenchay Hospital, Bristol, UK
Aims: Length of hospital stay for mastectomy patients has declined.
Hospital Episode Statistics data for 2010-11 showed the average length of
stay is still almost four days.Without compromising clinical care the aim of
this study was to evaluate the feasibility and safety of a new pathway
aimed at discharging patients within 24 hours of surgery.
Methods: From December 2008 suitable breast cancer patients requiring
mastectomy and/or major axillary surgery were offered same day admis-
sion and discharge home within 24 hours.
Results: 126 patients (mean age:60; range27-86) were included from 2008-
2011. 99(79%) underwent mastectomy with either axillary node sampling
(ANS) (10), sentinel lymph node biopsy (SNB)(59), axillary node clearance
(ANC)(20) or no axillary procedure (10). 4 (3%) had bilateral mastectomy
with either ANS(1), SNB(2) or no axillary procedure (1). (18%) patients
underwent ANCwith either wide local excision (4), repeat excision (1) or no
breast procedure (18). 97(77%) patients were discharged within 24 hours.
24(19%) were discharged on second day and 4(3%) required a three night
stay. One patient developed ventilatory problems post-operatively requiring
transfer to ITU. None of the 97 patients required unplanned readmission.
Conclusions: Major breast and axillary surgery can be safely performed
with a minimal length of post-operative stay in suitable patients.
0589: ONE-STAGE DELAYED BREAST RECONSTRUCTION USING
STRATTICE AND PERMANENT IMPLANT
Victoria Bonello, Siva Gopalswamy, Sheikh Ahmad. Royal Cornwall
Hospital, Truro, Cornwall, UK
Aim: This case series aims to determine the degree of patient satisfaction
and complication rates associated with a novel method of one-stage
delayed breast reconstruction. Method: Six patients underwent recon-
struction, one of which was bilateral, over an eight-month period.
StratticeTM was used to create a subpectoral/allogenic graft pocket capa-
cious enough to accommodate a permanent implant, hence eliminating
the need for further intervention following the index procedure. The
creation of a neo-inframammary fold was essential to produce a natural
looking result.
A patient satisfaction questionnaire was conducted six months following
the procedure.
The complication rate was determined after review of case notes.
Results: All patients showed satisfaction with the cosmetic outcome and
especially with the ease of return to normal activities. One early post-
operative complication was noted. This involved a small area of poor
wound healing at the site of previous irradiation, necessitating excision of
scar tissue.
Conclusion: This case series has demonstrated that this new technique is
an excellent option for patients wishing to undergo a less extensive form of
delayed reconstruction. It is associated with less tissue disruption than
other reconstructive procedures, hence reducing the length of recovery
and complication rates whilst giving the reconstructed breast a natural
appearance.0600: GYNECOMASTIA: IS IT COST-EFFECTIVE TO INVESTIGATE ALL
PATIENTS IN A FINANCIALLY RESTRAINED NHS?
Habib Tafazal, Hiren Chauhan, Mehboob Mirza. Sandwell General Hospital,
Birmingham, UK
Aim: Gynecomastia is a common condition, with manymen being referred
to the already busy rapid access breast clinic. As surgery for gynecomastia
is classed as non-essential, is it cost-effective to investigate all patients?
Method: Retrospective analysis of 97 patients referred from primary care.
All patients were male, aged 17 to 89 years. The costs of the following
investigations were calculated. Blood tests including LFTs, U&Es, TSH, FSH,
LH, prolactin, testosterone, oestradiol, AFP, HCG and imaging in the form of
mammography and ultrasound.
Results: The cost of a complete set of blood tests for each patient, including
stafﬁng and reagents, totals £35. Mammography and ultrasound cost £110
each. 87% of the patients were investigated with blood tests; the majority
of which were normal. 43% had a mammogram, 52% had an ultrasound.
Neither breast cancer nor endocrine pathology was detected in any cases.
Total cost of the blood tests was £3000; mammography costs were over
£4500.
Conclusions: Investigating all patients may not be cost effective but
a selected combination of tests may be useful. We recommend that blood
tests do not add value towards diagnosis and are an unnecessary additional
cost to the already ﬁnancially restrained NHS.
0649: A COMPLETE AUDIT CYCLE OF PREOPERATIVE SURGICAL SITE
MARKING VERIFICATION CHECKLIST
S. Anwar, R. Kurﬁ, S.S. Rajan, P. Webster, P. Turton, K. Horgan. Department
of Breast Surgery, Leeds General Inﬁrmary, The Leeds Teaching Hospitals NHS
Trust, Leeds, UK
Aims: Correct preoperative surgical site marking is a major patient safety
issue. The aim of this audit was to examine the compliance with preopera-
tive surgical site marking veriﬁcation checklist (PMVC) used at this trust.
Methods: A prospective audit (101-patients) and a re-audit following
staff education (125-patients) examined PMVC for correct written
conﬁrmation of: (a) side and procedure, (b) marking veriﬁcation checks
on ward (checks 1 and 2), and preoperatively in theatre (checks 3 and 4),
(d) safety net signings if any of checks 1-4 were not completed (checks 5
and 6).
Results: All patients had correct side and operation description listed.
Ward documentation for checks 1 and 2 were complete in 100% and 97% in
initial-audit, and in 100% and 98% in re-audit period, respectively. In
theatre documentation for checks 3 and 4were complete in 70% and 48% in
initial-audit, and in 80% and 74% in re-audit period. Further safety net-
checks 5 and 6 were not completed in either case (initial-audit¼58%,
re-audit¼36%). No inadvertent side surgery error occurred in either cohort.
Conclusions: A signiﬁcant improvement in practice was demonstrated
following staff education and regular close audit is necessary to ensure
compliance to PMVC which is pivotal in preventing error.
0664: IMPACT OF PROPHYLACTIC ANTIBIOTICS ON THE INCIDENCE OF
POST-OPERATIVE WOUND INFECTION AND SUBSEQUENT DELAY IN
ADJUVANT THERAPY FOR BREAST CANCER
Dilraj Bilku, Caroline Brammer. Royal Wolverhampton Hospital NHS Trust,
Wolverhampton, West Midlands, UK
Introduction: Breast surgery is considered clean but studies have shown
rates of infection to be 3% to 30%. Wound infection results in the delayed
start of adjuvant breast cancer treatment. We therefore conducted an audit
to analyse compliance with guidelines (SIGN guideline 84,104).
Methods: 68 patients undergoing radiotherapy following wide local
excision for breast cancer across four units were analysed. Data was
extracted from treatment sheets, operation notes and anaesthetic charts.
Results: Antibiotic prophylaxis was administered in 28 patients (41%) of
which six (21%) developed wound infection. No antibiotics were given
in 40 patients (59%) of which 20 (50%) developed wound infection.
There was a delay in the initiation of radiotherapy in 31 patients. In two
patients (7%) the delay was due to wound infection while in ten
patients (32%) the delay was due to wound infection and adjuvant
chemotherapy.
